NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
13 trialsNCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT00838539 2018-09-18
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT01378377 2018-07-30
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
EMD Serono
Phase 1 Terminated
NCT01827267 2018-07-03
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT01646021 2018-01-19
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed
NCT00083993 2011-11-08
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Terminated
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00062751 2011-04-15
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00235794 2007-12-27
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase NA Completed